ROCKVILLE, Md. & NEW YORK, August 02, 2024--(BUSINESS WIRE)--OS Therapies Incorporated ("OS Therapies" or the "Company") (NYSE-A: OSTX), a Cancer Immunotherapy and Antibody Drug Conjugate...
OS Therapies focuses on developing advanced treatments for osteosarcoma, addressing a significant unmet medical need.
With an estimated $1.72 billion market for osteosarcoma and a...
NurExone Biologics is developing exosome-based therapies for non-invasive treatment of central nervous system injuries, with their lead product, ExoPTEN, showing significant promise in preclinical...
RenovoTAMP™ Technology: Innovative targeted chemotherapy delivery system.
Clinical Validation: Supported by recent publications and new studies.
Market Potential: Positioned within a projected $220.5 billion cancer therapy...
TORONTO and HAIFA, Israel, June 28, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a...